Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› NSCLC (Non-small Cell Lung Cancer)
Clinical trial register · China

NSCLC (Non-small Cell Lung Cancer) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19224 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:17 UTC
19224
Studies in scope
all four open statuses
11811
Recruiting now
open to new participants
2030
Lead sponsors
across recruiting studies
Top sites
Shanghai 8 Guangzhou 5 Beijing 4 Hangzhou 3 Tianjin 3
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai8 Guangzhou5 Beijing4 Hangzhou3 Tianjin3
All 14 locations
Target enrolment
to

NSCLC (Non-small Cell Lung Cancer) trials in China

26 of 19224 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Hubei Cancer Hospital
Phase 2
29
Wuhan
2026-09-21
Recruiting
Betta Pharmaceuticals Co., Ltd.
Observational
2,572
Beijing, Shanghai
2026-09
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 3
300
Shanghai
2026-07-27
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
78
Guangzhou, Suqian, Shanghai, Hangzhou, Lishui
2026-06-25
Recruiting
Sun Yat-sen University
Phase 2
160
Guangzhou
2026-06-01
Recruiting
Tang-Du Hospital
Phase 2
60
Xi'an
2026-05-13
Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NCT07528274NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-05-01
Recruiting
Tang-Du Hospital
Phase 1/2
20
Xi’an
2026-03-25
Not yet open
Jemincare
Phase 3
472
Beijing
2025-12-31
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12-01
Recruiting
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
NCT07742332EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy
Peng Zhang
Phase 2
160
Shanghai
2025-11-25
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
Guangdong Association of Clinical Trials
Phase 2
115
Guangzhou, Chengdu
2025-11-05
Not yet open
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
NCT07182708NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
62
Beijing
2025-10-01
Recruiting
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
West China Hospital
Phase 1
10
Chengdu
2025-09-04
Recruiting
Avistone Pharmaceutical(Ningbo)Co., LTD.
Phase 1/2
108
Zhengzhou, Shanghai
2025-08-22
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2025-07-20
Recruiting
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT07376707CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
Hefei TG ImmunoPharma Co., Ltd.
Phase 1
194
Shanghai
2025-06-12
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
38
Tianjin
2025-04-01
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
30
Shanghai
2025-01-01
Recruiting
Guangdong Provincial People's Hospital
Phase 2
46
Guangzhou
2024-12-22
Recruiting
Fudan University
Observational
6,000
Shanghai
2024-12-01
Recruiting
Akeso
Phase 3
560
Jinan
2024-11-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
78
Hangzhou
2024-10-01
Active, closed
Avistone Biotechnology Co., Ltd.
Phase 2
139
Guangzhou
2023-07-21
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
Pfizer
Phase 2
430
Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou
2020-09-23
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/nsclc-non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,224 studies in total at the last sync on 11 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies listing the condition NSCLC (Non-small Cell Lung Cancer).

How many NSCLC (Non-small Cell Lung Cancer) trials are recruiting in China?

20 of the 26 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (NSCLC (Non-small Cell Lung Cancer)), 26 studies
PhaseStudiesRecruitingShare
Phase 2151057.7%
Phase 33211.5%
Observational227.7%
Phase 1227.7%
Phase 1/2227.7%
Not applicable113.8%
Phase 4113.8%

Most active sponsors

Lead sponsors with the most studies (NSCLC (Non-small Cell Lung Cancer))
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital33
Tang-Du Hospital22
Akeso11
Avistone Biotechnology Co., Ltd.10
Avistone Pharmaceutical(Ningbo)Co., LTD.11
Betta Pharmaceuticals Co., Ltd.11
Fudan University11
Genfleet Therapeutics (Shanghai) Inc.11
Guangdong Association of Clinical Trials11
Guangdong Provincial People's Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.